Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Prostate cancer exhibits common genetic alterations like ETS gene rearrangement and PTEN loss.
• Poly (ADP-ribose) polymerase (PARP) inhibitors have demonstrated single-agent activity in early-phase prostate cancer studies.
• PARP1 is implicated in androgen receptor (AR) signaling and ETS gene rearrangements, crucial pathways in prostate cancer.

Purpose of the Study:

• To review preclinical findings and early-phase clinical trials of PARP inhibitor-based therapies.
• To explore the potential of PARP inhibitors as a novel treatment paradigm for metastatic prostate cancer.
• To investigate the role of genetic alterations in prostate cancer sensitivity to PARP inhibitors.

Main Methods:

• Review of preclinical research on PARP inhibitors in prostate cancer models.
• Analysis of data from phase I clinical trials of PARP inhibitors.
• Examination of the molecular mechanisms linking PARP1, AR, and ETS alterations.

Main Results:

• Phase I studies indicate single-agent activity for PARP inhibitors in sporadic and BRCA-mutant prostate cancers.
• Preclinical models suggest enhanced sensitivity to PARP inhibitors with ETS gene rearrangement and PTEN loss.
• PARP1's role in AR transcriptional activity and ETS gene rearrangement is supported by emerging evidence.

Conclusions:

• PARP inhibitor therapy represents a promising new treatment strategy for metastatic prostate cancer.
• Genetic alterations, including BRCA mutations, ETS rearrangements, and PTEN loss, may predict response to PARP inhibitors.
• Further clinical investigation is warranted to establish PARP inhibitors in prostate cancer treatment paradigms.